Lee, Jong Hyuk
Choi, Yunhee
Hong, Hyunsook
Kim, Young Tae
Goo, Jin Mo
Kim, Hyungjin http://orcid.org/0000-0003-0722-0033
Funding for this research was provided by:
Seoul National University Hospital Research Fund (04-2020-2040, 03-2022-2170)
National Research Foundation of Korea (NRF-2020R1C1C1003684)
Article History
Received: 28 September 2022
Revised: 23 May 2023
Accepted: 18 July 2023
First Online: 31 August 2023
Declarations
:
: The scientific guarantor of this publication is Hyungjin Kim.
: Hyungjin Kim is a member of the European Radiology Editorial Board. They have not taken place in the review or selection process of his article.Activities not related to the present article: J.H.L. received consulting fees from Radisen; Y.T.K. received consulting fees from Johnson and Johnson; payment for lectures from AstraZeneca; holds stock option in Genome Insight. J.M.G. received research grants from Dongkook Lifescience, LG Electronics, and Coreline Soft. H.K. received a research grant from Lunit; consulting fees from RadiSen; holds stock and stock option in Medical IP.
: Two of the authors (Yunhee Choi and Hyunsook Hong) are biostatisticians.
: Written informed consent was waived by the Institutional Review Board.
: Institutional Review Board approval was obtained.
: Some of the study patients have been reported previously. However, none of the prior studies focused on the prognostic value of ground-glass opacity in lung cancers with freedom from recurrence and/or lung cancer-specific survival as study outcomes.
: • retrospective• diagnostic or prognostic study• performed at one institution